Search Results | NIH

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Search Results 2401 – 2420 of 3231

Tratamiento como Prevención (TasP)

https://clinicalinfo.hiv.gov/glossary/treatment-prevention-tasp

https://clinicalinfo.hiv.gov/contact-us

https://clinicalinfo.hiv.gov/contact-us

Coccidioidomycosis

https://clinicalinfo.hiv.gov/guidelines/hiv-clinical-guidelines-pediatric-opportunistic-infections/coccidioidomycosis

Talaromycosis (Formerly Penicilliosis)

https://clinicalinfo.hiv.gov/guidelines/hiv-clinical-guidelines-adult-and-adolescent-opportunistic-infections/talaromycosis

Human Papillomavirus Disease

https://clinicalinfo.hiv.gov/guidelines/hiv-clinical-guidelines-pediatric-opportunistic-infections/human-papillomavirus

Prepregnancy Counseling and Care

https://clinicalinfo.hiv.gov/guidelines/perinatal-hiv-clinical-guidelines/prepregnancy-counseling-and-care

Reproductive Options When One or Both Partners Have HIV

https://clinicalinfo.hiv.gov/guidelines/perinatal/prepregnancy-counseling-childbearing-age-reproductive-options-partners

Appendix B: Safety and Toxicity of Individual Antiretroviral Agents in Pregnancy

https://clinicalinfo.hiv.gov/guidelines/perinatal-hiv-clinical-guidelines/appendix-b-safety-and-toxicity-individual

Non-Nucleoside Reverse Transcriptase Inhibitors

https://clinicalinfo.hiv.gov/guidelines/perinatal-hiv-clinical-guidelines/non-nucleoside-reverse-transcriptase-inhibitors

https://clinicalinfo.hiv.gov/guidelines/hiv-clinical-guidelines-adult-and-adolescent-opportunistic-infections/tables

Table 4. Significant Pharmacokinetic Interactions Between Drugs Used to Treat or Prevent Opportunistic Infections

https://clinicalinfo.hiv.gov/guidelines/hiv-clinical-guidelines-adult-and-adolescent-opportunistic-infections/significant-drug-interactions

Guidelines Panel Members

https://clinicalinfo.hiv.gov/guidelines/pediatric-arv/guidelines-panel-members

https://clinicalinfo.hiv.gov/guidelines/perinatal-hiv-clinical-guidelines/archived-drugs

Amprenavir (Agenerase, APV)

https://clinicalinfo.hiv.gov/guidelines/perinatal/archived-drugs-amprenavir-agenerase

Cytomegalovirus Disease

https://clinicalinfo.hiv.gov/guidelines/hiv-clinical-guidelines-adult-and-adolescent-opportunistic-infections/cytomegalovirus

Limitations to Treatment Safety and Efficacy

https://clinicalinfo.hiv.gov/guidelines/hiv-clinical-guidelines-adult-and-adolescent-arv/limitations-treatment-safety-and

Adherence to the Continuum of Care

https://clinicalinfo.hiv.gov/guidelines/hiv-clinical-guidelines-adult-and-adolescent-arv/adherence-continuum-care

Considerations for Antiretroviral Use in People With Coinfections

https://clinicalinfo.hiv.gov/guidelines/hiv-clinical-guidelines-adult-and-adolescent-arv/considerations-antiretroviral-use

Tuberculosis/HIV Coinfection

https://clinicalinfo.hiv.gov/guidelines/hiv-clinical-guidelines-adult-and-adolescent-arv/coinfections-tuberculosis-hiv